Cargando…

The potential crosstalk between tumor and plasma cells and its association with clinical outcome and immunotherapy response in bladder cancer

BACKGROUND: Although immunotherapy is effective in improving the clinical outcomes of patients with bladder cancer (BC), it is only effective in a small percentage of patients. Intercellular crosstalk in the tumor microenvironment strongly influences patient response to immunotherapy, while the cros...

Descripción completa

Detalles Bibliográficos
Autores principales: Long, Fei, Wang, Wei, Li, Shuo, Wang, Bicheng, Hu, Xin, Wang, Jun, Xu, Yaqi, Liu, Min, Zhou, Junting, Si, Huaqi, Xi, Xiaodan, Meng, Xiang-yu, Yuan, Chunhui, Wang, Fubing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10155334/
https://www.ncbi.nlm.nih.gov/pubmed/37138324
http://dx.doi.org/10.1186/s12967-023-04151-1
_version_ 1785036305847025664
author Long, Fei
Wang, Wei
Li, Shuo
Wang, Bicheng
Hu, Xin
Wang, Jun
Xu, Yaqi
Liu, Min
Zhou, Junting
Si, Huaqi
Xi, Xiaodan
Meng, Xiang-yu
Yuan, Chunhui
Wang, Fubing
author_facet Long, Fei
Wang, Wei
Li, Shuo
Wang, Bicheng
Hu, Xin
Wang, Jun
Xu, Yaqi
Liu, Min
Zhou, Junting
Si, Huaqi
Xi, Xiaodan
Meng, Xiang-yu
Yuan, Chunhui
Wang, Fubing
author_sort Long, Fei
collection PubMed
description BACKGROUND: Although immunotherapy is effective in improving the clinical outcomes of patients with bladder cancer (BC), it is only effective in a small percentage of patients. Intercellular crosstalk in the tumor microenvironment strongly influences patient response to immunotherapy, while the crosstalk patterns of plasma cells (PCs) as endogenous antibody-producing cells remain unknown. Here, we aimed to explore the heterogeneity of PCs and their potential crosstalk patterns with BC tumor cells. METHODS: Crosstalk patterns between PCs and tumor cells were revealed by performing integrated bulk and single-cell RNA sequencing (RNA-seq) and spatial transcriptome data analysis. A risk model was constructed based on ligand/receptor to quantify crosstalk patterns by stepwise regression Cox analysis. RESULTS: Based on cell infiltration scores inferred from bulk RNA-seq data (n = 728), we found that high infiltration of PCs was associated with better overall survival (OS) and response to immunotherapy in BC. Further single-cell transcriptome analysis (n = 8; 41,894 filtered cells) identified two dominant types of PCs, IgG1 and IgA1 PCs. Signal transduction from tumor cells of specific states (stress-like and hypoxia-like tumor cells) to PCs, for example, via the LAMB3/CD44 and ANGPTL4/SDC1 ligand/receptor pairs, was validated by spatial transcriptome analysis and associated with poorer OS as well as nonresponse to immunotherapy. More importantly, a ligand/receptor pair-based risk model was constructed and showed excellent performance in predicting patient survival and immunotherapy response. CONCLUSIONS: PCs are an important component of the tumor microenvironment, and their crosstalk with tumor cells influences clinical outcomes and response to immunotherapies in BC patients. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-023-04151-1.
format Online
Article
Text
id pubmed-10155334
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-101553342023-05-04 The potential crosstalk between tumor and plasma cells and its association with clinical outcome and immunotherapy response in bladder cancer Long, Fei Wang, Wei Li, Shuo Wang, Bicheng Hu, Xin Wang, Jun Xu, Yaqi Liu, Min Zhou, Junting Si, Huaqi Xi, Xiaodan Meng, Xiang-yu Yuan, Chunhui Wang, Fubing J Transl Med Research BACKGROUND: Although immunotherapy is effective in improving the clinical outcomes of patients with bladder cancer (BC), it is only effective in a small percentage of patients. Intercellular crosstalk in the tumor microenvironment strongly influences patient response to immunotherapy, while the crosstalk patterns of plasma cells (PCs) as endogenous antibody-producing cells remain unknown. Here, we aimed to explore the heterogeneity of PCs and their potential crosstalk patterns with BC tumor cells. METHODS: Crosstalk patterns between PCs and tumor cells were revealed by performing integrated bulk and single-cell RNA sequencing (RNA-seq) and spatial transcriptome data analysis. A risk model was constructed based on ligand/receptor to quantify crosstalk patterns by stepwise regression Cox analysis. RESULTS: Based on cell infiltration scores inferred from bulk RNA-seq data (n = 728), we found that high infiltration of PCs was associated with better overall survival (OS) and response to immunotherapy in BC. Further single-cell transcriptome analysis (n = 8; 41,894 filtered cells) identified two dominant types of PCs, IgG1 and IgA1 PCs. Signal transduction from tumor cells of specific states (stress-like and hypoxia-like tumor cells) to PCs, for example, via the LAMB3/CD44 and ANGPTL4/SDC1 ligand/receptor pairs, was validated by spatial transcriptome analysis and associated with poorer OS as well as nonresponse to immunotherapy. More importantly, a ligand/receptor pair-based risk model was constructed and showed excellent performance in predicting patient survival and immunotherapy response. CONCLUSIONS: PCs are an important component of the tumor microenvironment, and their crosstalk with tumor cells influences clinical outcomes and response to immunotherapies in BC patients. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-023-04151-1. BioMed Central 2023-05-03 /pmc/articles/PMC10155334/ /pubmed/37138324 http://dx.doi.org/10.1186/s12967-023-04151-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Long, Fei
Wang, Wei
Li, Shuo
Wang, Bicheng
Hu, Xin
Wang, Jun
Xu, Yaqi
Liu, Min
Zhou, Junting
Si, Huaqi
Xi, Xiaodan
Meng, Xiang-yu
Yuan, Chunhui
Wang, Fubing
The potential crosstalk between tumor and plasma cells and its association with clinical outcome and immunotherapy response in bladder cancer
title The potential crosstalk between tumor and plasma cells and its association with clinical outcome and immunotherapy response in bladder cancer
title_full The potential crosstalk between tumor and plasma cells and its association with clinical outcome and immunotherapy response in bladder cancer
title_fullStr The potential crosstalk between tumor and plasma cells and its association with clinical outcome and immunotherapy response in bladder cancer
title_full_unstemmed The potential crosstalk between tumor and plasma cells and its association with clinical outcome and immunotherapy response in bladder cancer
title_short The potential crosstalk between tumor and plasma cells and its association with clinical outcome and immunotherapy response in bladder cancer
title_sort potential crosstalk between tumor and plasma cells and its association with clinical outcome and immunotherapy response in bladder cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10155334/
https://www.ncbi.nlm.nih.gov/pubmed/37138324
http://dx.doi.org/10.1186/s12967-023-04151-1
work_keys_str_mv AT longfei thepotentialcrosstalkbetweentumorandplasmacellsanditsassociationwithclinicaloutcomeandimmunotherapyresponseinbladdercancer
AT wangwei thepotentialcrosstalkbetweentumorandplasmacellsanditsassociationwithclinicaloutcomeandimmunotherapyresponseinbladdercancer
AT lishuo thepotentialcrosstalkbetweentumorandplasmacellsanditsassociationwithclinicaloutcomeandimmunotherapyresponseinbladdercancer
AT wangbicheng thepotentialcrosstalkbetweentumorandplasmacellsanditsassociationwithclinicaloutcomeandimmunotherapyresponseinbladdercancer
AT huxin thepotentialcrosstalkbetweentumorandplasmacellsanditsassociationwithclinicaloutcomeandimmunotherapyresponseinbladdercancer
AT wangjun thepotentialcrosstalkbetweentumorandplasmacellsanditsassociationwithclinicaloutcomeandimmunotherapyresponseinbladdercancer
AT xuyaqi thepotentialcrosstalkbetweentumorandplasmacellsanditsassociationwithclinicaloutcomeandimmunotherapyresponseinbladdercancer
AT liumin thepotentialcrosstalkbetweentumorandplasmacellsanditsassociationwithclinicaloutcomeandimmunotherapyresponseinbladdercancer
AT zhoujunting thepotentialcrosstalkbetweentumorandplasmacellsanditsassociationwithclinicaloutcomeandimmunotherapyresponseinbladdercancer
AT sihuaqi thepotentialcrosstalkbetweentumorandplasmacellsanditsassociationwithclinicaloutcomeandimmunotherapyresponseinbladdercancer
AT xixiaodan thepotentialcrosstalkbetweentumorandplasmacellsanditsassociationwithclinicaloutcomeandimmunotherapyresponseinbladdercancer
AT mengxiangyu thepotentialcrosstalkbetweentumorandplasmacellsanditsassociationwithclinicaloutcomeandimmunotherapyresponseinbladdercancer
AT yuanchunhui thepotentialcrosstalkbetweentumorandplasmacellsanditsassociationwithclinicaloutcomeandimmunotherapyresponseinbladdercancer
AT wangfubing thepotentialcrosstalkbetweentumorandplasmacellsanditsassociationwithclinicaloutcomeandimmunotherapyresponseinbladdercancer
AT longfei potentialcrosstalkbetweentumorandplasmacellsanditsassociationwithclinicaloutcomeandimmunotherapyresponseinbladdercancer
AT wangwei potentialcrosstalkbetweentumorandplasmacellsanditsassociationwithclinicaloutcomeandimmunotherapyresponseinbladdercancer
AT lishuo potentialcrosstalkbetweentumorandplasmacellsanditsassociationwithclinicaloutcomeandimmunotherapyresponseinbladdercancer
AT wangbicheng potentialcrosstalkbetweentumorandplasmacellsanditsassociationwithclinicaloutcomeandimmunotherapyresponseinbladdercancer
AT huxin potentialcrosstalkbetweentumorandplasmacellsanditsassociationwithclinicaloutcomeandimmunotherapyresponseinbladdercancer
AT wangjun potentialcrosstalkbetweentumorandplasmacellsanditsassociationwithclinicaloutcomeandimmunotherapyresponseinbladdercancer
AT xuyaqi potentialcrosstalkbetweentumorandplasmacellsanditsassociationwithclinicaloutcomeandimmunotherapyresponseinbladdercancer
AT liumin potentialcrosstalkbetweentumorandplasmacellsanditsassociationwithclinicaloutcomeandimmunotherapyresponseinbladdercancer
AT zhoujunting potentialcrosstalkbetweentumorandplasmacellsanditsassociationwithclinicaloutcomeandimmunotherapyresponseinbladdercancer
AT sihuaqi potentialcrosstalkbetweentumorandplasmacellsanditsassociationwithclinicaloutcomeandimmunotherapyresponseinbladdercancer
AT xixiaodan potentialcrosstalkbetweentumorandplasmacellsanditsassociationwithclinicaloutcomeandimmunotherapyresponseinbladdercancer
AT mengxiangyu potentialcrosstalkbetweentumorandplasmacellsanditsassociationwithclinicaloutcomeandimmunotherapyresponseinbladdercancer
AT yuanchunhui potentialcrosstalkbetweentumorandplasmacellsanditsassociationwithclinicaloutcomeandimmunotherapyresponseinbladdercancer
AT wangfubing potentialcrosstalkbetweentumorandplasmacellsanditsassociationwithclinicaloutcomeandimmunotherapyresponseinbladdercancer